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SIR—Jamain et al1 reported a frameshift and a mis
sense mutation in the X-linked neuroligin 4 (NLGN4,
MIM# 300427) and neuroligin 3 (NLGN3, MIM#
300336) genes, respectively, in Swedish families with
autism. A frameshift mutation in NLGN4 appeared
de novo in the mother, cosegregated with an affected
brother with Asperger syndrome and was absent in
a normal brother. This frameshift mutation was not
present in 600 unrelated control X-chromosomes.
A missense mutation in NLGN3, R451C, was found
in the mother and two sibs, one with autism and
another with Asperger syndrome, but no other
relatives were studied. It was not found in 300
unrelated control X-chromosomes.
Laumonnier et al2 reported a large French family in
which 10 males had nonspecific X-linked mental
retardation, two had autism and one had pervasive
developmental disorder. All affected patients were
found to have the same frameshift mutation (1253de-
lAG) in the NLGN4 gene. One obligate female carrier
had mild mental retardation.
The NLGN3 and NLGN4 genes map to Xq13 and
Xp22.3, respectively. The NLGN3 gene spans 32 kb,
and the NLGN4 gene spans 338 kb. NLGN3 has eight
exons, encoding two alternatively spliced isoforms of
828 and 848 amino acids.3 The NLGN4 gene contains
six exons and codes for a protein of 816 amino acids.
All neuroligins contain an N-terminal hydrophobic
sequence with the characteristics of a cleaved signal
peptide followed by a large esterase homology
domain, a highly conserved single transmembrane
region, and a short cytoplasmic domain.4
To better understand the relationship between the
NLGN4 gene and autism, the coding regions and
associated splice junctions of the NLGN4 gene were
scanned for mutations with DOVAM-S (Detection of
Virtually All Mutations-SSCP) and direct sequencing
in the following subjects: 148 unrelated patients with
autism (76 Midwest US Caucasians and 72 Portuguese
Caucasians; 122 males and 26 females), 48 patients
without autism, including 24 Midwest US Caucasian
patients with attention deficit hyperactivity disorder
(ADHD)5 and 24 UK Caucasian patients with DSM-IV
Bipolar I Disorder (BPD),6 as well as 48 Portuguese
healthy control subjects.
The Portuguese autistic patients were diagnosed
using DSM-IV criteria, the Autism Diagnostic Inter-
view-Revised (ADI-R) and the Childhood Autism
Rating Scale (CARS). Idiopathic subjects were inclu-
ded in the study after clinical assessment and
screening for known medical and genetic conditions
associated with autism (fragile X, chromosomal
disorders, neurocutaneous syndromes, metabolic
disorders, infectious diseases). Neuropsychological
evaluation was performed using the Ruth Griffiths
Mental Developmental Scales or the Wechsler Intelli-
gence Scale for Children (WISC), depending on the
patient’s age. The Midwest autistic patients were
diagnosed as described previously.7
Putative missense mutations were identified once
each in the NLGN4 gene in four separate autistic
patients (Table 1). G99S and K378R were found in
unrelated Portuguese patients. V403M and R704C
were found in unrelated Midwest patients. G99, K378
and V403 are located in the esterase domain and R704
is located in the cytoplasmic domain.4 Three of the
structural changes, K378R, V403M and R704C, occur
in asymptomatic mothers, while G99S occurs in a
mother with learning disability.
Comprehensive mutation scanning of 48 Portuguese
healthy controls and sequencing of the appropriate
exons in 288 healthy controls including 96 Portuguese
and 192 Midwest US Caucasians (144 males and 192
females; 528 X-chromosomes total) did not reveal
these four missense variants or any other structural
changes (4/148 vs 0/336, P¼ 0.009 or 4/174 vs 0/528,
P¼ 0.004, when the Fisher exact test is performed
with patients or X-chromosome alleles, respectively).
In addition, no structural variants were found in a
pilot experiment performed on patients with ADHD
and BPD (24 of each).
Patient #1 has a younger brother with a diagnosed
language disability and a global developmental
quotient below the mean (Ruth Griffiths Mental
Developmental Scales score of 89), who also carries
the G99S variation. Their mother, who is hetero-
zygous for the variation, had a documented learning
disability. As also found by Laumonnier et al,
sequence variation in NLGN4 may be segregating
with autism and cognitive disability in this family.
Patient #3 had an affected brother with V403M. He
had three other unaffected sibs, including a sister
without the variant and two brothers with V403M
who had normal social function (making friends
easily), normal school performance and no attentional
problems, consistent with an absence of cosegregation
between this variant and any phenotype. The three
unaffected children had Social Communication Ques-
tionnaire (SCQ) (Lifetime)8 scores of 0. Proband #3
was specifically of Irish descent. In all, 50 normal
female controls of Irish descent were sequenced, none
of them had V403M.
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Table 1 Structural variants identified in the NLGN4 gene
ID NT change A.A
change
Conservationa Clinical information Family membersb
#1 759 G4A G99S NLGN2/3/4/4Y Portuguese Caucasian, female Mother: þ / Father: þ
Diagnosed at age 3 years with severe autism (the CARS score was 52, and scores on
the three domains of the ADI-R, social interaction, nonverbal communication and
repetitive behaviors were 26, 12 and 4, respectively) and mental retardation (GDQ
of 31, with a cognitive profile characteristic of autistic children: performance DQ of
39 and language DQ of 18). The patient belongs to a large sibship, with the mother,
who also carries the variant, and four sibs reporting learning disability without
autism
Mother has learning
disability.
A brother with
language disability: 
Patient #1 has a younger brother with a diagnosed language disability and a global
developmental quotient below the mean (Ruth Griffiths Mental Developmental Scales
score of 89), who also carries the G99S variation. Their mother, who is heterozygous
for the variation, had a documented learning disability. As also found by Laumonnier
et al, sequence variation in NLGN4 may be segregating with autism and cognitive
disability in this family
#2 1597 A4G K378R NLGN1/2/3/4/4Y Portuguese Caucasian, male Mother: þ / Father: þ
Diagnosed at age 4 years with mild autism (scores on the ADI-R domains of social
interaction, verbal communication and repetitive behaviors were 20, 12 and 5,
respectively), with normal IQ. The parents reported regression from age 2 years in
language development and social interaction skills. There was no family history of
neurological or psychiatric disease
#3 1671 G4A V403M NLGN1/2/3/4/4Y Midwest Caucasian, male Mother: þ / Father: þ
Drosophila NL Diagnosed at age 4 years with PDD NOSd (scores on ADI-R domains of social
interaction, verbal communication, and repetitive and restricted behaviors were
10, 9 and 7, respectively) with ratio nonverbal IQ of 84 and ratio verbal IQ of 79;
ADOS was consistent with PDD NOS; head circumference 53.3 cm at 39 months
Affected brother: 
(Autistic disorder)
Unaffected brothers
(2): 
Patient #3 had an affected brother with V403M. He had three other unaffected
sibs, including a sister without the variant and two brothers with V403M who had
normal social function (making friends easily), normal school performance, and no
attentional problems, consistent with an absence of cosegregation between this
variant and any phenotype
#4c 2574 C4T R704C NLGN1/3/4/4Y Midwest Caucasian, male Mother: þ / Father: þ
Diagnosed at age 6 years with autistic disorder (scores on ADI-R domains of social
interaction, verbal communication, and repetitive and restricted behaviors were
27, 22 and 10, respectively) with nonverbal IQ of 85
Sister with PDD NOS:
þ
Unaffected sister:þ /
ADOS was consistent with autistic disorder; head circumference 52.9 cm at 6 years
One sister has PDD NOS, and the other, her dizygotic twin, is unaffected. A paternal
first cousin has autism
aEach of the amino-acid change is at residue strictly conserved in either four or five of the five members of the neuroligin gene family.
bþ wild type allele;  variant allele; þ / heterozygotes.
cR704C was discovered in one of 52 Midwest autism patients for which whole genome amplification was performed with multiple displacement amplification (MDA).
The 52 MDA amplified samples passed stringent quality control.14 The presence of R704C also was confirmed from remaining original genomic DNA.
dPDD NOS—Pervasive developmental disorder not otherwise specified.
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The lack of cosegregation of V403M suggests
caution in interpreting the results and highlights the
need for future work. V403M may not be of functional
significance. However, incomplete penetrance for
V403M seems the likely conclusion, because case–
control association studies routinely detect incom-
plete penetrance, for example, a hypothetical pene-
trance of 25%, which is compatible with segregation
in this family, implies a 200-fold relative risk of
autism imparted by V403M. Indeed, this case–control
design cannot a priori distinguish full from partial
penetrance. In addition, the epidemiological and
biological context of our work is consistent with the
interpretation that missense variants with incomplete
penetrance predispose to autism as follows: (i)
incomplete penetrance is the rule in psychiatric
diseases (eg BPD, schizophrenia, autism) as the
concordance (or concordance for disease spectrum
phenotypes) found in monozygotic twins can vary
from 43 to 92% and typically is 15% or lower in
dizygotic twins who share similar environment and
half of the genes;9–11 (ii) the strict conservation of
V403 in the five members of the neuroligin family
(representing 2þ billion years of evolutionary diver-
gence12,13) suggests that amino-acid substitution at
V403 is deleterious; (iii) the affected sibs have
V403M, consistent with a single genetic mechanism
as generally expected in a single family with this
uncommon disease (0.2% incidence) and (iv) the
current case–control studies complement the data of
Jamain et al1 and Laumonnier et al2 that strongly
suggest protein-truncating mutations predispose to
autism. Efforts are underway to ascertain extended
families of the four probands and to characterize them
clinically and genetically. Demonstration of cosegre-
gation in all affected individuals will be helpful to
confirm the putative association of each variant with
autism. If the association is confirmed, study of
unaffected individuals will allow an estimate of
penetrance.
Patient #4 has two sisters who are dizygotic twins.
One sister has PDD NOS (pervasive developmental
disorder not otherwise specified), close but not quite
mild mental retardation and lacks R704C. The other
sister is heterozygous for R704C and is not affected.
The lack of R704C inherited from the mother in the
sister with PDD NOS seemingly falsifies the putative
association, unless autism, autism spectrum disorder
or mental retardation occurs in the paternal lineage.
Indeed, exploration of the paternal lineage reveals
that one of two paternal first cousins has autism.
Thus, two genetic mechanisms may operate in this
family. More work is needed to interpret the segrega-
tion pattern in this family.
No structural variants were found in the NLGN3
gene when the 96 unrelated patients with autism (24
Midwest and 72 Portuguese), 24 ADHD and 24 BPD
patients were analyzed.
In conclusion, scanning and sequencing of 2.5 Mb
of the NLGN3 and NLGN4 genes reveals an associa-
tion of NLGN4 structural variants at highly conserved
amino acids with an estimated attributable risk for
autism of about 3% in these cohorts. This study
suggests that missense changes in neuroligin 4 may
contribute to autism susceptibility as well as the
protein-truncating mutations reported by Jamain et al1
and Laumonnier et al.2
Autism and language disability were present in
hemizygous male relatives and a learning disability
was present in one of four heterozygous mothers. The
presence of V403M in two normal brothers raises
the distinct possibility of incomplete penetrance.
Male relatives with a missense change have language
disability, autism or normal function, while female
relatives who are heterozygous for a missense variant
are normal, or have a learning disability. Incomplete
penetrance has important clinical implications, for
example, the presence of an NLGN4 mutation in a
fetus does not necessarily imply autism or mental
retardation.
GenBank Accession numbers:
The following protein sequences were used:
AAM46112 for NLGN4, AAM46113 for NLGN4Y,
AAF71230 for NLGN3, AAH32555 for NLGN1,
AAM46111 for NLGN2 and AAF52450 for Drosophila
neuroligin.
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SIR—Interferon-a (IFN-a), the most effective treatment
for chronic hepatitis by virus C (HCV), induces
depression, anxiety, and fatigue.1–3 We report here
that depression and anxiety have different time
courses compared to fatigue, and that patients
experiencing more severe fatigue are less likely to
respond to IFN-a by clearing the virus.
We studied all patients who started pegylated IFN-a
(pegIFN-a-2b, 1.5 mg/kg, weekly, s.c.) and ribavirin
(400 mg, b.d.) between February and July 2001: n¼ 29,
23 males and six females; 23 Caucasians; mean (SD)
age 4377 years; 16 virus genotype 1, 13 virus
genotype non-1. All subjects were HCV RNA positive,
with histological evidence, by liver biopsy, of moder-
ate or severe HCV-related injury. Treatment lasted 24
weeks for genotype non-1, and 48 weeks for genotype
1. In all, 18 patients (64%; one subject was lost to
follow-up) were identified as sustained virologic
responders, as indicated by serum HCV RNA un-
detectable (o100 copies/ml, Roche Amplicor System)
at 24 weeks after the end of treatment. Approval was
received from Kings College Hospital Research Ethics
committee.
To monitor psychiatric adverse effects and quality
of life, four self-report questionnaires were adminis-
tered at baseline, weekly for the first 4 weeks of
treatment, and four-weekly thereafter until the end
of therapy: the Beck Depression Inventory (BDI),4 the
Stait and Trait Anxiety Inventory (STAI),5 Chalder’s
Fatigue Questionnaire (CFQ);6 and three items from
the SF-36 (physical role limitation, emotional role
limitation, and physical function).7 At baseline, the
scores were: BDI, 1279; STAI (added scores), 87721;
CFQ, 1675; and SF-36 (added scores), 242777. Nine
patients (31%) described a previous psychiatric
history and were all included in the study; four
patients were taking an antidepressant at baseline and
continued with this throughout the treatment. The
results of the questionnaires during the treatment
were modeled as a polynomial function of time,
generating curves fitted through all available points,
describing both courses over time and changes from
baseline using summary measures.
During the treatment, depression and anxiety
increased linearly with time (depression: t(26)¼4.3,
Po0.001; anxiety: t(26)¼ 3.1, P¼ 0.004). Therefore,
we used the slopes of the regression lines as summary
measures. At 24 weeks, the estimated increases were
4.5 on the BDI (95% CI: 2.4–6.6) and 8.6 on the STAI
(3.0–14.3). In contrast, fatigue increased, and quality
of life decreased, predominantly during the first
8 weeks of treatment, while the curves remained
relatively flat at later time points (fatigue: t(25)¼3.3,
P¼0.003; quality of life: t(25)¼7.4, Po0.001).
Therefore, we used the differences between 8 weeks
and baseline as summary measures. At 8 weeks,
the estimated increase in the CFQ was 3.5 (1.3–5.7),
and the estimated decrease in the SF-36 was 117.8
(85.1–150.5). Of note is that Capuron et al8 examined
patients treated with IFN-a for malignant melanoma,
and also found that fatigue (with anorexia and pain)
appears earlier than depression and anxiety. How-
ever, we are the first to describe that the reduction
in quality of life follows the course of the fatigue,
rather than that of depression or anxiety. Interestingly,
better quality of life at baseline predicted a larger
reduction in quality of life during the treatment
(P¼ 0.046).
Baseline mental state did not predict virologic
response (all P-values 40.5), but changes in mental
state did. Specifically, the 10 patients who did not
respond had had greater deterioration in all four
psychological variables during the treatment. This
reached statistical significance for fatigue: the
CFQ increase at 8 weeks was 7.4 in nonresponders
and only 2.3 in responders (CI for the difference:
1.1–9.1; P¼ 0.016). This result is particularly striking
as the fatigue was measured months before the time in
which the viral response was measured. Moreover,
this was not due to a difference in virus genotypes in
responders vs nonresponders, as changes in mental
state were not associated with virus genotype (all
P-values 40.5). Although these are preliminary
findings in a small sample, our findings are consistent
Scientific Correspondence
332
Molecular Psychiatry
